Sudden outcomes on weight reduction and breast most cancers from a global research in JNCCN

IMAGE: JNCCN February 2021 cover picture More

Image Credit: NCCN

PLYMOUTH MEETING, PA [February 16, 2021] New research in the February 2021 issue of JNCCN – Journal of the National Comprehensive Cancer Network examined body mass index (BMI) data for people with HER2-positive early breast cancer and found 5% weight loss in patients over two years of age in was associated with poorer results. Weight gain over the same period had no effect on survival rates.

“The finding that weight loss, not weight gain, was associated with worse results is unexpected,” said lead researcher Samuel Martel, MD, Universitè de Sherbrooke, Quebec, Canada, who worked with researchers in Belgium, Brazil, Germany, Italy. Switzerland and the United Kingdom, and the National Cancer Institute and Mayo Clinic in the United States. “We could not distinguish between intentional and unintentional weight loss, so it is a matter of speculation whether worse results are due to weight loss or vice versa. We hope our results underscore the importance of including consecutive and prolonged data collection on weight.” in oncological studies and a better understanding of metabolic processes after cancer diagnosis, which can affect the results. “

The BMI data comes from the ALTTO BIG 2-06 study, which collected height and weight data from 8,381 patients with HER2-positive early-stage breast cancer treated with chemotherapy plus trastuzumab and / or lapatinib. 2.2% were underweight at the start of treatment, 45.3% were of normal weight, 32.1% were classified as overweight, another 20.4% were obese – defined as having a BMI greater than 30. Initial obesity was with poorer results including more frequent and more common serious adverse events leading to discontinuation of treatment and significantly poorer overall survival rates.

“It was surprising to see that greater than 5% weight loss after 2 years was associated with poorer distance disease-free survival. Is our general advice to obese / overweight patients to exercise and lose weight wrong?” interviewed Anthony D. Elias, MD, University of Colorado Cancer Center, member of the NCCN Panel on Clinical Practice Guidelines (R) for Breast Cancer. “Careful examination of the Kaplan-Meier hazard charts suggests that the relapse curves for those with weight loss are steeper in the second and third years of follow-up, but relatively parallel thereafter. It is possible that the weight loss observed early is an indication of an impending relapse of breast cancer. “

The study highlights the importance of weight management for cancer survival. The authors hope that their results will form the basis for further research and oncology studies to guide weight control during survival.

###

To read the full study, visit JNCCN.org. Free access to “Body Mass Index and Weight Change in Patients with HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Study” is available until May 10, 2021.

Via JNCCN – Journal of the National Comprehensive Cancer Network

More than 25,000 oncologists and other cancer researchers in the United States read the JNCCN – Journal of the National Comprehensive Cancer Network. This peer-reviewed, indexed medical journal provides the latest information on innovations in translational medicine, as well as scientific studies related to research in oncological health services, including quality care and value, bioethics, comparative and cost efficiency, public policy and interventional Research on supportive care and survival. JNCCN provides updates to the NCCN Clinical Practice in Oncology (NCCN Guidelines®), policy recommendation reviews, health service research, and case reports highlighting molecular insights in patient care. JNCCN is published by Harborside. Visit JNCCN.org. To find out if you are eligible for a FREE subscription to JNCCN, please visit http://www.nccn.org/jnccn/subscribe.aspx. Follow JNCCN on Twitter @JNCCN.

Via the National Comprehensive Cancer Network

The National Comprehensive Cancer Network® (NCCN®) is a non-profit alliance of leading cancer centers dedicated to patient care, research and education. NCCN’s goal is to improve and facilitate quality, effective, efficient, and accessible cancer treatment so that patients can lead better lives. The NCCN Guidelines for Clinical Practice in Oncology (NCCN Guidelines®) contain transparent, evidence-based consensus recommendations from experts in cancer treatment, prevention and support services. They are the recognized standard for clinical direction and policy in cancer management and the most thorough and most frequently updated guidelines for clinical practice available in all areas of medicine. The NCCN Guidelines for Patients® provide cancer treatment information from experts to educate and empower patients and caregivers through the support of the NCCN Foundation®. NCCN also promotes continuing education, global initiatives, policy and research collaboration, and publication in oncology. Visit NCCN.org for more information and follow NCCN on Facebook @NCCNorg, Instagram @NCCNorg and Twitter @NCCN.

Disclaimer: AAAS and EurekAlert! are not responsible for the correctness of the press releases published on EurekAlert! by contributing institutions or to use information through the EurekAlert system.

Comments are closed.